|Table of Contents|

The clinical efficacy of different combinations of chemoradiotherapy and the conversion therapy efficacy of chemoradiotherapy in the initially unresectable locally advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
99-103
Research Field:
Publishing date:

Info

Title:
The clinical efficacy of different combinations of chemoradiotherapy and the conversion therapy efficacy of chemoradiotherapy in the initially unresectable locally advanced gastric cancer
Author(s):
DING Tong1; DONG Hongming1; 2; 3; WANG Wenling1; 2; 3; WANG Gang1; 2; 3; CHEN Weiwei1; 2; 3; LI Xiaokai1; 2; 3; CHEN Wanghua1; 2; 3; LI Guodong1; 2; 3
1.Guizhou Medcial University,Guizhou Guiyang 550004,China；2.Department of Cancer Oncology,the Affiliated Hospital of Guizhou Medcial University,Guizhou Guiyang 550004,China；3.Department of Abdomen Oncology,the Affiliated Cancer Hospital of Guizhou Medcial University,Guizhou Guiyang 550004,China.
Keywords:
initially unresectable locally advanced gastric cancer; synchronous chemoradiotherapy; sequential chemoradiotherapy; conversion therapy; clinical efficacy
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.01.018
Abstract:
Objective:To analysis the clinical efficacy and the situation of conversion therapy of chemoradiotherapy in the initially unresectable locally advanced gastric cancer,compared the clinical efficacy between synchronous chemoradiotherapy and sequential chemoradiotherapy.Methods:We retrospectively investigated 75 patients with nitially unresectable locally advanced gastric cancer who were admitted to the The Affiliated Cancer Hospital of Guizhou Medical University from June 2010 to June 2020，including synchronous chemoradiotherapy group(33 cases) and sequential radiotherapy group(42 cases),observe the clinical efficacy and the success rate of conversion therapy of chemoradiotherapy,and compare the clinical efficacy between synchronous chemoradiotherapy and sequential chemoradiotherapy.Results:The objective response rate(ORR) was 53.3%，disease control rate（DCR）was 85.3%，conversion therapy rate was 30.7%.The ORR of synchronous chemoradiotherapy group and sequential radiotherapy group were 66.7% and 42.9%，the difference was statistically significant(P＜0.05).Synchronous chemoradiotherapy group had a better conversion rate than sequential chemoradiotherapy group,but the difference was not statistically significant(P＞0.05).Median survival time（MST） of patients without conversion surgery was 14.3 months，the 1-year survival rate and 2-years survival rate were 63.5% and 15.4%，synchronous chemoradiotherapy group had better a survival than sequential chemoradiotherapy group,but the difference was not statistically significant(P＞0.05).For patients achieved conversion therapy，the survival situation in R0 resection patients is obviously better than patients with R1/R2 resection（P＜0.05）.Conclusion:For patients with initially unresectable locally advanced gastric cancer,chemoradiotherapy is an effective treatment,that can make some patients achieved conversion surgery that prolonged survival.Synchronous chemoradiotherapy significantly improved the objective efficiency compared with sequential chemoradiotherapy,and tended to improve the rate of conversion therapy.

References:

[1]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
[2］HAO J,CHEN Y,FAN J,et al.CSCO.Guidelines of Chinese society of clinical on cology(csco) gastric cancer 2021［EB/OL］.CSCO,2021,［2021-07-01］.http://www.csco.org.cn/cn/index.aspx.
[3］AJANI JA,D'AMICO TA,ALMHANNA K,et al.NCCN.The NCCN gastric cancer clinical practice guidelines in oncology［EB/OL］.Fort Washington:NCCN,2022(version 1) ［2021-12-20］.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434.
[4]LIU Y,ZHAO G,XU Y,et al.Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer［J］.Int J Radiat Oncol Biol Phys,2017,98(5):1096-1105.
[5]TAKI T,HOYA Y,WATANABE A,et al.Usefulness of chemoradiotherapy for inoperable gastric cancer［J］.Ann R Coll Surg Engl,2017,99(4):332-336.
[6]王琴,董洪敏,王文玲,等.序贯化放疗治疗局部晚期胃癌的临床疗效［J］.现代肿瘤医学,2017,25(16):2605-2609. WANG Q,DONG HM,WANG WL,et al.Clinical efficacy observation of sequential chemoradiotherapy for locally advanced gastric cancer ［J］.Modern Oncology,2017,25(16):2605-2609.
[7］熊慧如,董洪敏,王文玲,等.序贯化放疗治疗局部晚期胃癌的近期疗效［J］.贵阳医学院学报，2013,38(5):515-517. XIONG HR,DONG HM,WANG WL,et al.Short-term efficacy of sequential chemoradiotherapy for locally advanced gastric cancer ［J］.Journal of Guiyang Medical College,2013,38(5):515-517.
[8］WANG J,XU R,LI J,et al.Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer［J］.Gastric Cancer,2016,19(1):234-244.
[9］姚俊涛,刘瑜,刘秋芳,等.同步放化疗对不能手术局部晚期胃癌的疗效［J］.现代肿瘤医学,2015,23(18):2637-2640. YAO JT,LIU Y,LIU QF,et al.Efficacy of chemoradiation in the advanced gastric carcinoma patients without operation［J］.Modern Oncology,2015,23(18):2637-2640.
[10］TIAN SP,YUAN YJ,SHI SX,et al.The observation of curative effect of concurrent chemoradiotherapy in the treatment of patients with advanced gastric cancer［J］.Journal of Basic and Clinical Oncology,2011,24(1):35-36.
[11］HINGORANI M,DIXIT S,JOHNSON M,et al.Palliative radiotherapy in the presence of well-controlled metastatic disease after initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer［J］.Cancer Res Treat,2015,47(4):706-717.
[12］BODA-HEGGEMANN J,WEISS C,SCHNEIDER V,et al.Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall and disease-free survival in advanced gastric cancer［J］.Strahlenther Onkol,2013,189(5):417-423.
[13］TEY J,CHOO BA,LEONG CN,et al.Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era［J］.Medicine,2014,93(22):e118.
[14］LI R,HOU WH,CHAO J,et al.Chemoradiation improves survival compared with chemotherapy alone in unresected nonmetastatic gastric cancer［J］.J Natl Compr Cane Netw,2018,16(8):950-958．
[15］盛华明.序贯放化疗与单纯化疗治疗局部晚期胃癌的疗效对比［J］.川北医学院学报,2017,32(05):753-755. SHENG HM.Comparison of clinical efficacy of sequential radiochemotherapy and single chemotherapy in the treatment of regional advanced gastric cancer［J］.Journal of North Sichuang Medical College,2017,32(05):753-755.
[16］WANG X,JIN J.Research progress in palliative radiotherapy for advanced gastric cancer［J］.Chinese Journal of Radiation Oncology,2016,25(1):85-89.
[17]SATO Y,OHNUMA H,NOBUOKA T,et al.Conversion therapy for inoperable advanced gastric cancer patients by docetaxel,cisplatin,and S-1(DCS) chemotherapy:a multi-institutional retrospective study［J］.Gastric Cancer,2017,20(3):517-526.
[18］YAMAGUCHI K,YOSHIDA K,TANAHASHI T,et al.The long-term survival of stage IV gastric cancer patients with conversion therapy［J］.Gastric Cancer,2018,21(2):315-323.
[19]MORGAGNI P,SOLAINI L,FRAMARINI M,et al.Conversion surgery for gastric cancer:A cohort study from a western center［J］.Int J Surg,2018,53:360-365.
[20］ELIZABETH C SMYTH,MAGNUS NILSSON,HEIKE I GRABSCH,et al.Gastric cancer［J］.The Lancet,2020,396:635-648.
[21］LI K,ZHANG A,LI X,et al.Advances in clinical immunotherapy for gastric cancer［J］.Biochim Biophys Acta Rev Cancer,2021,1876(2):271-284.

Memo

Memo:
贵州省科技厅基金项目(编号:黔科合J字［2009］2218号)
Last Update: 2022-11-30